Myasthenia Gravis Therapeutics Pipeline 2017

1
Myasthenia Gravis Therapeutics Pipeline to have
Maximum Drugs to be Developed as Biologics
2
Myasthenia Gravis Therapeutics
According to a new research report Myasthenia
Gravis Therapeutics Pipeline Analysis, 2017 -
Clinical Trials Results, Patent, Designation,
Collaboration, and Other Developments published
by PS Market Research, Myasthenia Gravis
currently exhibits a pipeline of 19 drug
candidates. Browse Detailed Summary at
https//www.psmarketresearch.com/market-analysis/m
yasthenia-gravis-therapeutics-pipeline-analysis
3
Myasthenia Gravis Therapeutics
Myasthenia Gravis Therapeutics Pipeline in 2017
The study analysed that the therapeutics pipeline
comprises of approximately 19 drug candidates in
different stages of development. Myasthenia
gravis is a chronic autoimmune disorder that acts
on neuromuscular junction and leads to the
weakening of skeletal muscles. This causes loss
of muscle control in moving the body parts, such
as the movement of arms and legs, breathing, loss
of eye movements, chewing, talking, and
swallowing. The situation of the disease worsens
after a period of activity and improves after a
period of rest.
4
Myasthenia Gravis Therapeutics
Strategic Collaboration for the Development of
Myasthenia Gravis Therapeutics
Various companies, educational institutes and
medical organizations are collaborating for the
development of drugs for the treatment of this
disease. For instance, Merck Co., Inc. entered
into a multi-targeted collaboration and license
agreement with Ra Pharmaceuticals, Inc. to use
the latters drug discovery technology platform
for the development of orally available cyclic
peptides for the treatment of myasthenia gravis.
5
Myasthenia Gravis Therapeutics
Various Drug Candidates are Being Developed as
Biologics
It has been observed that most of the drugs in
the myasthenia gravis therapeutics pipeline, are
being developed from the natural source. NT-1654
is a heparan sulfate proteoglycan, and is under
development by Neurotune AG for the treatment of
myasthenia gravis. The drug acts as a
neuromuscular junction stimulator. Some of the
key players developing drugs for the treatment of
myasthenia gravis include Alexion
Pharmaceuticals, Inc., CSL Behring LLC, Novartis
AG and others.
6
Myasthenia Gravis Therapeutics
Download report sample at
https//www.psmarketresearch.com/market-analysis/m
yasthenia-gravis-therapeutics-pipeline-analysis/re
port-sample
7
GET IN TOUCH
THANK YOU!
For information regarding permissions and other
queries Kindly write to
US/Canada Toll-Free 1-888-778-7886